Abilify Whistleblowers Want 6th Circ. To Revive FCA Suit
By Kat Sieniuc ( August 19, 2016, 4:45 PM EDT) -- Two whistleblowers urged the Sixth Circuit on Friday to reverse a lower court's dismissal of their False Claims Act suit against Otsuka America Pharmaceutical Inc. and Bristol-Myers Squibb Co. over the off-label promotion of the antipsychotic drug Abilify, saying that the companies' argument that their claims are precluded by a public disclosure bar is wrong....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.